Bladder Cancer

Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center
VIDEOS
Enfortumab Vedotin Plus Pembrolizumab Induces High Response Rates in Cisplatin-Ineligible Patients With Urothelial Cancer
09/20/2022
Jonathan Rosenberg, MD, reviews findings from a cohort study evaluating enfortumab vedotin monotherapy or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible patients with urothelial cancer.
Jonathan Rosenberg, MD, reviews findings from a cohort study evaluating enfortumab vedotin monotherapy or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible patients with urothelial cancer.
Jonathan Rosenberg, MD, reviews...
09/20/2022
Oncology
News
Improvements in Bladder Cancer Mortality in the US Are Not Equitably Distributed
02/24/2022
An overall decrease in the incidence of bladder cancer mortality in the United States was not shared among micropolitan (rural) populations, revealing Black and rural populations experienced a significant worsening of mortality, presented at...
An overall decrease in the incidence of bladder cancer mortality in the United States was not shared among micropolitan (rural) populations, revealing Black and rural populations experienced a significant worsening of mortality, presented at...
An overall decrease in the...
02/24/2022
Oncology
Dr Martinez Chanza
Videos
Avelumab-Based Neoadjuvant Chemotherapy for Patients With Non–Metastatic, Muscle-Invasive Bladder Cancer: AURA Trial
11/11/2021
Nieves Martínez Chanzá, MD, PhD, discusses the AURA trial evaluating avelumab as the basis of neoadjuvant chemotherapy in platinum-eligible and ineligible patients with non-metastatic muscle-invasive bladder cancer.
Nieves Martínez Chanzá, MD, PhD, discusses the AURA trial evaluating avelumab as the basis of neoadjuvant chemotherapy in platinum-eligible and ineligible patients with non-metastatic muscle-invasive bladder cancer.
Nieves Martínez Chanzá, MD, PhD,...
11/11/2021
Oncology
Dr Powles
Videos
Dr Powles Reviews NORSE Study Results in FGFR3, FGFR2 Genetically Altered mUC
10/27/2021
Thomas Powles, MRCP, MD, discusses evaluating erdafitinib in combination with cetrelimab in patients with locally advanced or mUC with FGFR3 or FGFR2 genetic alterations ineligible for cisplatin.
Thomas Powles, MRCP, MD, discusses evaluating erdafitinib in combination with cetrelimab in patients with locally advanced or mUC with FGFR3 or FGFR2 genetic alterations ineligible for cisplatin.
Thomas Powles, MRCP, MD,...
10/27/2021
Oncology
Dr
Videos
Dr Grivas Discusses Updates from the JAVELIN Bladder 100 Trial
06/29/2021
Petros Grivas, MD, PhD, highlights updates from the phase III JAVELIN Bladder 100 trial for advanced urothelial carcinoma.
Petros Grivas, MD, PhD, highlights updates from the phase III JAVELIN Bladder 100 trial for advanced urothelial carcinoma.
Petros Grivas, MD, PhD,...
06/29/2021
Oncology
mm
Videos
Dr Grivas Discusses Trial Results of Nivolumab or Lirilumab for MIBC
06/27/2021
Petros Grivas, MD, PhD, discusses phase Ib trial results of neoadjuvant nivolumab or lirilumab for cisplatin-ineligible patients with MIBC.
Petros Grivas, MD, PhD, discusses phase Ib trial results of neoadjuvant nivolumab or lirilumab for cisplatin-ineligible patients with MIBC.
Petros Grivas, MD, PhD,...
06/27/2021
Oncology
No DFS Benefit With Adjuvant Atezolizumab for High-Risk Urothelial Carcinoma
Podcasts
No DFS Benefit With Adjuvant Atezolizumab for High-Risk Urothelial Carcinoma
02/12/2021
Petros Grivas, MD, PhD, talks about the importance of the IMvigor010 clinical trial, which assessed the use of adjuvant atezolizumab in patients with muscle-invasive urothelial cancer.
Petros Grivas, MD, PhD, talks about the importance of the IMvigor010 clinical trial, which assessed the use of adjuvant atezolizumab in patients with muscle-invasive urothelial cancer.
Petros Grivas, MD, PhD, talks...
02/12/2021
Oncology
Maintenance Avelumab With Best Supportive Care Improves OS in Urothelial Cancer
Videos
Maintenance Avelumab With Best Supportive Care Improves OS in Urothelial Cancer
05/31/2020
Petros Grivas, MD, PhD, discusses interim findings from the phase 3 JAVELIN Bladder 100 clinical trial presented at the virtual 2020 ASCO Annual Meeting.
Petros Grivas, MD, PhD, discusses interim findings from the phase 3 JAVELIN Bladder 100 clinical trial presented at the virtual 2020 ASCO Annual Meeting.
Petros Grivas, MD, PhD,...
05/31/2020
Oncology
News
Radical Cystectomy, PLND Safe After Neoadjuvant Pembrolizumab for Bladder Cancer
01/23/2020
Study findings support the safety of radical cystectomy and PLND in patients with nonmetastatic bladder cancer who received neoadjuvant pembrolizumab.
Study findings support the safety of radical cystectomy and PLND in patients with nonmetastatic bladder cancer who received neoadjuvant pembrolizumab.
Study findings support the...
01/23/2020
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use